Regeneron Pharmaceuticals, Inc. vs Geron Corporation: Examining Key Revenue Metrics

Biotech Giants: Regeneron's Growth vs. Geron's Stability

__timestampGeron CorporationRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201411530002819557000
Thursday, January 1, 2015363710004103728000
Friday, January 1, 201661620004860427000
Sunday, January 1, 201710650005872227000
Monday, January 1, 201810660006710800000
Tuesday, January 1, 20194600007863400000
Wednesday, January 1, 20202530008497100000
Friday, January 1, 2021139300016071700000
Saturday, January 1, 202259600012172900000
Sunday, January 1, 202323700013117200000
Monday, January 1, 202414202000000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Regeneron vs. Geron

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Regeneron Pharmaceuticals, Inc. has demonstrated a remarkable trajectory, with its revenue surging by over 360% from 2014 to 2023. In contrast, Geron Corporation's revenue has remained relatively stagnant, peaking in 2015 and experiencing fluctuations thereafter.

Regeneron's Meteoric Rise

Regeneron's revenue growth is a testament to its innovative pipeline and strategic partnerships. By 2023, the company achieved a revenue of approximately $13.1 billion, a significant leap from $2.8 billion in 2014. This growth underscores Regeneron's position as a leader in the biotech industry.

Geron's Steady Path

Geron, on the other hand, has faced challenges in scaling its operations. Despite a peak in 2015, its revenue has not surpassed $1.4 million in recent years, highlighting the competitive nature of the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025